For example, at a concentration of 5 μM, the percentages of cell viability of H1299 (vector) and H1299 (EGFR-WT) were about 80%, while that of H1299 (EGFR–L858R) dramatically decreased to 40% (Figure 2C), which further confirmed that like Gefitinib, NSCLC cell's sensitivity to WB-308 also increased after the EGFR L858R mutation was present. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.